Gastric Cancer Clinical Trial
— DRTSTOfficial title:
Does the Technique of Duodenal Resection Affect the Incidence of Duodenal Stump Fistula After Gastrectomy for Gastric Cancer ? A Randomized Controlled Trial (DRTST: Duodenal Resection Tri-staple Technology)
The goal of this trial is to demonstrate that the use of Tri-Staple Technology for duodenal
resection during open gastrectomy for cancer is safer than the use of other conventional
methods of resection/closure of the duodenum and that the incidence of duodenal fistula can
be decreased to that observed after the use of this technology in Laparoscopic and robotic
gastrectomy, therefore almost three times lower than that currently reported in literature.
Participating centres must have an annual volume of at least 20 gastrectomies per year.
Status | Recruiting |
Enrollment | 700 |
Est. completion date | October 1, 2019 |
Est. primary completion date | September 11, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - pathologically proven malign tumor of the stomach - age of 18 to 80 years, - no history of other cancers - no history of radiotherapy in supra-mesocolic space - total or distal gastrectomy without anastomosis with the duodenum Exclusion Criteria: - emergency surgery - American Society of Anesthesiologists class > 3 - need for combined resection of other organs - laparoscopic/robotic access - severe heart disease - liver cirrhosis - T stage >cT4a - citology positive at preoperative laparoscopy - cM+ (clinical suspicion of distant metastasis) - cD+ (clinical suspicion of duodenal involvment) |
Country | Name | City | State |
---|---|---|---|
Italy | San Luigi University Hospital | Orbassano | Turin |
Lead Sponsor | Collaborator |
---|---|
University of Turin, Italy |
Italy,
Aurello P, Bellagamba R, Rossi Del Monte S, D'Angelo F, Nigri G, Cicchini C, Ravaioli M, Ramacciato G. Apoptosis and microvessel density in gastric cancer: correlation with tumor stage and prognosis. Am Surg. 2009 Dec;75(12):1183-8. — View Citation
Aurello P, Magistri P, Nigri G, Petrucciani N, Novi L, Antolino L, D'Angelo F, Ramacciato G. Surgical management of microscopic positive resection margin after gastrectomy for gastric cancer: a systematic review of gastric R1 management. Anticancer Res. 2014 Nov;34(11):6283-8. Review. — View Citation
Chander J, Lal P, Ramteke VK. Rectus abdominis muscle flap for high-output duodenal fistula: novel technique. World J Surg. 2004 Feb;28(2):179-82. Epub 2004 Jan 20. — View Citation
Cozzaglio L, Cimino M, Mauri G, Ardito A, Pedicini V, Poretti D, Brambilla G, Sacchi M, Melis A, Doci R. Percutaneous transhepatic biliary drainage and occlusion balloon in the management of duodenal stump fistula. J Gastrointest Surg. 2011 Nov;15(11):197 — View Citation
Cozzaglio L, Coladonato M, Biffi R, Coniglio A, Corso V, Dionigi P, Gianotti L, Mazzaferro V, Morgagni P, Rosa F, Rosati R, Roviello F, Doci R. Duodenal fistula after elective gastrectomy for malignant disease : an italian retrospective multicenter study. — View Citation
EDMUNDS LH Jr, WILLIAMS GM, WELCH CE. External fistulas arising from the gastro-intestinal tract. Ann Surg. 1960 Sep;152:445-71. — View Citation
Inghelmann R, Grande E, Francisci S, Verdecchia A, Micheli A, Baili P, Capocaccia R, De Angelis R. Regional estimates of stomach cancer burden in Italy. Tumori. 2007 Jul-Aug;93(4):367-73. — View Citation
Isik B, Yilmaz S, Kirimlioglu V, Sogutlu G, Yilmaz M, Katz D. A life-saving but inadequately discussed procedure: tube duodenostomy. Known and unknown aspects. World J Surg. 2007 Aug;31(8):1616-24; discussion 1625-6. — View Citation
Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park DJ, Song KY, Lee SI, Ryu SY, Lee JH, Lee HJ; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Decreased Morbidity of Laparoscopic Distal Gastrectomy Compa — View Citation
Levy E, Cugnenc PH, Frileux P, Hannoun L, Parc R, Huguet C, Loygue J. Postoperative peritonitis due to gastric and duodenal fistulas. Operative management by continuous intraluminal infusion and aspiration: report of 23 cases. Br J Surg. 1984 Jul;71(7):54 — View Citation
Martin RC 2nd, Jaques DP, Brennan MF, Karpeh M. Achieving RO resection for locally advanced gastric cancer: is it worth the risk of multiorgan resection? J Am Coll Surg. 2002 May;194(5):568-77. — View Citation
McCulloch P, Ward J, Tekkis PP; ASCOT group of surgeons; British Oesophago-Gastric Cancer Group. Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study. BMJ. 2003 Nov 22;327(7425):1192-7 — View Citation
Milias K, Deligiannidis N, Papavramidis TS, Ioannidis K, Xiros N, Papavramidis S. Biliogastric diversion for the management of high-output duodenal fistula: report of two cases and literature review. J Gastrointest Surg. 2009 Feb;13(2):299-303. doi: 10.10 — View Citation
Musicant ME, Thompson JC. The emergency management of lateral duodenal fistula by pancreaticoduodenectomy. Surg Gynecol Obstet. 1969 Jan;128(1):108-14. — View Citation
Orsenigo E, Bissolati M, Socci C, Chiari D, Muffatti F, Nifosi J, Staudacher C. Duodenal stump fistula after gastric surgery for malignancies: a retrospective analysis of risk factors in a single centre experience. Gastric Cancer. 2014 Oct;17(4):733-44. d — View Citation
Pedrazzani C, Marrelli D, Rampone B, De Stefano A, Corso G, Fotia G, Pinto E, Roviello F. Postoperative complications and functional results after subtotal gastrectomy with Billroth II reconstruction for primary gastric cancer. Dig Dis Sci. 2007 Aug;52(8) — View Citation
Rossi JA, Sollenberger LL, Rege RV, Glenn J, Joehl RJ. External duodenal fistula. Causes, complications, and treatment. Arch Surg. 1986 Aug;121(8):908-12. — View Citation
Tarazi R, Coutsoftides T, Steiger E, Fazio VW. Gastric and duodenal cutaneous fistulas. World J Surg. 1983 Jul;7(4):463-73. — View Citation
Ujiki GT, Shields TW. Roux-en-Y operation in the management of postoperative fistula. Arch Surg. 1981 May;116(5):614-7. — View Citation
Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008 Nov 11;337:a2390. doi: 10.1136/bmj.a2390. — View Citation
* Note: There are 20 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | incidence of duodenal stump leak | The aim of this study is to evaluate if duodenal stump closure using tri-staple technology can significantly decrease the incidence of duodenal stump leakage to 1% as compared to other conventional methods (5%). So the primary endpoint is : - incidence of DSF, diagnosed on the basis of the presence of duodenal juice in the surgical drainage or its leakage through the abdominal wall, and confirmed by CT scan and/or fistulography. |
within 30/60 days from operation | |
Secondary | cost of surgery | cost of devices, hospital stay, drugs, examinations | within 90 days from operation | |
Secondary | operative time for duodenal stump closure | time ( min) necessary for duodenal stump closure | intraopeartively | |
Secondary | short-term postoperative complications | onset of postoperative complications according to Clavien-Dindo classification | within 30 days from operation | |
Secondary | blood loss | intraoperative blood loss (ml) | intraopeartively | |
Secondary | lenght of hospitalization | duration (days) of hospital stay after operation | 120 days after operation | |
Secondary | Operative mortality | post-operative death | 30 and 60 days after operation | |
Secondary | Frequency of DSF by surgical volume | rate of duodenal stump leak of every participating center | one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |